

4 h if warranted. Max 30 mg/day. **Schizophrenia**, oral therapy: start 5 to 10 mg/day PO. Target dose is 10 mg/day. Max 20 mg/day; however, doses above 10 mg/day have not been shown to be more effective. Reduce to 5 mg in debilitated patients or those predisposed to hypotension. **Schizophrenia**, long-acting injection: dose based on prior oral dose and ranges from 150 mg to 300 mg deep IM (gluteal) q 2 weeks or 300 mg to 405 mg q 4 weeks. See prescribing information. **Bipolar disorder, monotherapy for acute manic or mixed episodes or maintenance**: start 10 to 15 mg/day PO. Increase by 5 mg/day at intervals of 24 h or more if needed. Usual effective dose range 5 to 20 mg/day, max 20 mg/day. **Bipolar disorder, adjunctive for acute manic or mixed episodes**: start 10 mg/day PO; usual effective dose is 5 to 20 mg/day, max 20 mg/day. **Bipolar depression**, olanzapine + fluoxetine given separately: start 5 mg olanzapine + 20 mg fluoxetine daily in the evening. Increase to usual range of 5 to 12.5 mg olanzapine plus 20 to 50 mg fluoxetine as tolerated. Also see Symbyax combination product entry. **Treatment-resistant depression**, olanzapine + fluoxetine given separately: start 5 mg olanzapine + 20 mg fluoxetine daily in the evening. Increase to usual range of 5 to 20 mg olanzapine plus 20 to 50 mg fluoxetine as tolerated. See also Symbyax combination product entry. [Generic/Trade: tabs 2.5, 5, 7.5, 10, 15, 20 mg. Tabs, orally disintegrating (Zyprexa Zydis) 5, 10, 15, 20 mg. Trade only: long-acting injection (Zyprexa Relprevv) 210, 300, 405 mg/vial.] ▶L ♀ Neonates exposed in 3rd trimester at risk for withdrawal and extrapyramidal effects. ▶—\$■

PALIPERIDONE (Invega Trinza, Invega, Invega Sustenna) **Schizophrenia and schizoaffective disorder** (adjunctive and monotherapy): start 6 mg PO q am. 3 mg/day may be sufficient in some. May increase by 3 mg/day q 5 or more days to max 12 mg/day. Extended-release injection. **Schizophrenia (Invega Sustenna)**: Start 234 mg IM (deltoid) and then 156 mg IM 1 week later. Recommended monthly dose 117 mg IM (deltoid or gluteal) or within range of 39 to 234 mg, based on response. Patient must be able to tolerate oral paliperidone or risperidone prior to starting Sustenna. **Schizophrenia (Invega Trinza)**: use only after tolerability to Invega Sustenna has been established for at least 4 months. The dose of Trinza is given IM q 3 months based on the prior dose of Sustenna. For Sustenna 78 mg, use Trinza 273 mg; Sustenna 117 mg, use Trinza 410 mg; Sustenna 156 mg, use Trinza 546 mg; and Sustenna 234 mg, use Trinza 819 mg. Adjust dose at intervals of 3 months. **Schizoaffective disorder (Invega Sustenna)**: start 234 mg IM (deltoid) and then 156 mg IM on day 8. Usual dose range 78 to 234 mg, max 234 mg. [Generic/Trade: extended-release tabs 1.5, 3, 6, 9 mg. Trade only: depot formulation (Sustenna): 39, 78, 117, 156, 234 mg. Depot formulation (Trinza) 273, 410, 546, 819 mg.] ▶KL ♂ ♀ ▶—\$\$\$\$\$■

PIMAVANSERIN (Nuplazid) 34 mg PO once daily. Reduce to 10 mg/day in the presence of strong CYP3A4 inhibitors. [Trade only: tabs 10 mg. Caps 34 mg.] ▶L ♂ ♀ ???/?? ? \$\$\$\$\$

QUETIAPINE (Seroquel, Seroquel XR) **Schizophrenia**: start 25 mg PO two times per day (regular tabs); increase by 25 to 50 mg two to three times per day on days 2 and 3, and then to target dose of 300 to 400 mg/day divided two to three times per day on day 4. Usual effective dose is 150 to 750 mg/day, max 750 mg/day initial therapy

(cont.)